HRP20190847T1 - Dugodjelujući superagonisti glikoproteinskog hormona - Google Patents
Dugodjelujući superagonisti glikoproteinskog hormona Download PDFInfo
- Publication number
- HRP20190847T1 HRP20190847T1 HRP20190847TT HRP20190847T HRP20190847T1 HR P20190847 T1 HRP20190847 T1 HR P20190847T1 HR P20190847T T HRP20190847T T HR P20190847TT HR P20190847 T HRP20190847 T HR P20190847T HR P20190847 T1 HRP20190847 T1 HR P20190847T1
- Authority
- HR
- Croatia
- Prior art keywords
- valine
- asparagine
- threonine
- amino acid
- alpha subunit
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title claims 8
- 108090000288 Glycoproteins Proteins 0.000 title claims 8
- 229940088597 hormone Drugs 0.000 title claims 6
- 239000005556 hormone Substances 0.000 title claims 6
- 230000002483 superagonistic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 235000001014 amino acid Nutrition 0.000 claims 24
- 229940024606 amino acid Drugs 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 239000004475 Arginine Substances 0.000 claims 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 18
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 15
- 239000004474 valine Substances 0.000 claims 13
- 239000004473 Threonine Substances 0.000 claims 9
- 102000008175 FSH Receptors Human genes 0.000 claims 8
- 108010060374 FSH Receptors Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 6
- 241000283690 Bos taurus Species 0.000 claims 5
- 241000283073 Equus caballus Species 0.000 claims 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 230000007547 defect Effects 0.000 claims 4
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 231100000535 infertility Toxicity 0.000 claims 4
- 208000000509 infertility Diseases 0.000 claims 4
- 230000036512 infertility Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 206010068168 androgenetic alopecia Diseases 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 231100000545 luteal phase defect Toxicity 0.000 claims 2
- 229940040129 luteinizing hormone Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015124 ovarian disease Diseases 0.000 claims 2
- 201000004535 ovarian dysfunction Diseases 0.000 claims 2
- 231100000543 ovarian dysfunction Toxicity 0.000 claims 2
- 230000016087 ovulation Effects 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (19)
1. Polipeptid alfa podjedinice odabran iz skupine koja se sastoji od polipeptida divljeg tipa goveđe alfa podjedinice (SEQ ID NO:2), polipeptida divljeg tipa ovčje alfa podjedinice (SEQ ID NO:3), polipeptida divljeg tipa konjske alfa podjedinice (SEQ ID NO:4) i polipeptida divljeg tipa svinjske alfa podjedinice (SEQ ID NO:5), pri čemu spomenuti polipeptid alfa podjedinice sadrži:
(A) umetak amino kiseline koji pruža potencijalno mjesto glikosilacije, pri čemu je spomenuti umetak smješten odmah nakon pozicije 6 ili 7 spomenutog polipeptida alfa jedinice; i
(B) jednu ili više od sljedećih supstitucija amino kiseline divljeg tipa spomenutog polipeptida alfa jedinice s osnovnom amino kiselinom:
(i) amino kiselina divljeg tipa na poziciji 15 supstituirana je Argininom (R),
(ii) amino kiselina divljeg tipa na poziciji 17 SEQ ID NO: 2, 3 ili 5 supstituirana je Argininom (R),
(iii) amino kiselina divljeg tipa na poziciji 18 supstituirana je Argininom (R), Lizinom (K) ili Histidinom (H),
(iv) amino kiselina divljeg tipa na poziciji 20 supstituirana je Argininom (R), i
(v) amino kiselina divljeg tipa na poziciji 24 supstituirana je Argininom (R).
2. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što je spomenuti umetak dužine jedne do osam amino kiselina.
3. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što je spomenuti umetak odabran iz skupine koja se sastoji od:
(A) Asparagin (N);
(B) Treonin (T);
(C) Cistein (C);
(D) Asparagin-Valin (NV);
(E) Treonin-Asparagin-Valin (TNV);
(F) Treonin-Izoleucin-Asparagin-Valin-Treonin (TINVT);
(G) Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (NVTINV) (SEQ ID NO:1);
(H) Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin-Treonin (NVTINVT);
(I) Treonin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (TNVTINV) (SEQ ID NO: 12); te
(J) Valin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin-Treonin (VNVTINVT) (SEQ ID NO:20).
4. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što je spomenuta osnovna amino kiselina histidin, lizin,ili arginin.
5. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što je spomenuta osnovna amino kiselina arginin.
6. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što spomenuti polipeptid alfa podjedinice sadrži jednu, dvije, tri, četiri ili pet supstitucija.
7. Polipeptid alfa podjedinice prema zahtjevu 3, naznačen time što spomenuti polipeptid alfa podjedinice sadrži dva ili tri umetka.
8. Goveđi, ovčji, svinjski ili konjski polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što spomenuti polipeptid alfa jedinice sadrži:
(A) umetak amino kiseline koji pruža potencijalno mjesto glikosilacije, pri čemu je spomenuti umetak smješten odmah nakon pozicije 6 ili 7 spomenutog polipeptida alfa jedinice, i pri čemu je spomenuti umetak odabran iz skupine koja se sastoji od:
(a) Asparagin (N);
(b) Treonin (T);
(c) Cistein (C);
(d) Asparagin-Valin (NV);
(e) Treonin-Asparagin-Valin (TNV);
(f) Treonin-Izoleucin-Asparagin-Valin-Treonin (TINVT);
(g) Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (NVTINV) (SEQ ID NO:1);
(h) Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin-Treonin (NVTINVT);
(i) Treonin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (TNVTINV) (SEQ ID NO: 12); te
(j) Valin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin-Treonin (VNVTINVT) (SEQ ID NO:20); i
(B) barem jednu supstituciju amino kiseline divljeg tipa s osnovnom amino kiselinom, pri čemu je spomenuta supstitucija odabrana iz skupine koja se sastoji od:
(i) amino kiselina divljeg tipa na poziciji 15 supstituirana je Argininom (R),
(ii) amino kiselina divljeg tipa na poziciji 17 SEQ ID NO: 2, 3 ili 5 supstituirana je Argininom (R),
(iii) amino kiselina divljeg tipa na poziciji 18 supstituirana je Argininom (R), Lizinom (K) ili Histidinom (H),
(iv) amino kiselina divljeg tipa na poziciji 20 supstituirana je Argininom (R), i
(v) amino kiselina divljeg tipa na poziciji 24 supstituirana je Argininom (R).
9. Goveđi, ovčji, svinjski ili konjski polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što se pojavljuju jedna ili više od sljedećih supstitucija:
(A) amino kiselina divljeg tipa na poziciji 15 supstituirana je Argininom (R),
(B) amino kiselina divljeg tipa na poziciji 17 SEQ ID NO: 2, 3 ili 5 supstituirana je Argininom (R),
(C) amino kiselina divljeg tipa na poziciji 18 supstituirana je Argininom (R), Lizinom (K) ili Histidinom (H),
(D) amino kiselina divljeg tipa na poziciji 20 supstituirana je Argininom (R), i
(E) amino kiselina divljeg tipa na poziciji 24 supstituirana je Argininom (R),
te gdje je odmah nakon pozicije 6 spomenutog polipeptida alfa podjedinice umetnut jedan od sljedećih polipeptida:
(a) Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (NVTINV) (SEQ ID NO:1);
(b) Treonin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (TNVTINV) (SEQ ID NO: 12);
(c) Valin-Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin-Treonin (VNVTINVT) (SEQ ID NO:20);
(d) Asparagin-Valin (NV); i
(e) Treonin-Asparagin-Valin (TNV).
10. Polipeptid alfa podjedinice prema zahtjevu 1, zahtjevu 3 ili zahtjevu 8, naznačen time što spomenuti polipeptid alfa podjedinice sadrži sekvencu amino kiselina sa barem 80 %, 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 % ili 99 % identiteta sa sekvencom odabranom iz skupine koja se sastoji od SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 i SEQ ID NO: 10.
11. Modificirani glikoproteinski hormon koji sadrži polipeptid alfa podjedinice prema zahtjevu 1, zahtjevu 3, zahtjevu 8 ili zahtjevu 9, i beta podjedinicu luteinizirajućeg hormona (LH), korionskog gonadotropina (CG), hormona za stimulaciju folikula (FSH) ili hormona koji stimulira štitnjaču (TSH).
12. Modificirani glikoproteinski hormon koji sadrži polipeptid alfa podjedinice prema zahtjevu 1, zahtjevu 3, zahtjevu 8 ili zahtjevu 9, i beta podjedinicu hormona za stimulaciju folikula (FSH).
13. Modificirani glikoproteinski hormon koji sadrži polipeptid alfa podjedinice prema zahtjevu 1, zahtjevu 3, zahtjevu 8 ili zahtjevu 9 za uporabu u liječenju disfunkcije jajnika, defekata luteinske faze, neobjašnjene neplodnosti, neplodnosti radi muškog faktora, vremenski ograničenog začeća, niske ekspresije FSH receptora, niske osjetljivosti FSH receptora, nedostataka u vezanju FSH receptora, nedostataka u uparivanju FSH receptora, niske proizvodnje testosterona, muške ćelavosti po uzorku ili zatajenja ili ozljede hipofize.
14. Modificirani glikoprotein prema zahtjevu 11 ili zahtjevu 12 za uporabu u liječenju disfunkcije jajnika, defekata luteinske faze, neobjašnjene neplodnosti, neplodnosti radi muškog faktora, vremenski ograničenog začeća, niske ekspresije FSH receptora, niske osjetljivosti FSH receptora, nedostataka u vezanju FSH receptora, nedostataka u uparivanju FSH receptora, niske proizvodnje testosterona, muške ćelavosti po uzorku ili zatajenja ili ozljede hipofize.
15. Ne-terapeutski postupak stimuliranja ovulacije u ne-ljudskoj životinji, koji sadrži primjenu modificiranog glikoproteinskog hormona koji sadrži polipeptid alfa podjedinice prema zahtjevu 1, zahtjevu 3, zahtjevu 8 ili 9 spomenutoj životinji.
16. Ne-terapeutski postupak stimuliranja ovulacije u ne-ljudskoj životinji, koji sadrži primjenu modificiranog glikoproteina prema zahtjevu 11 ili zahtjevu 12 spomenutoj životinji.
17. Modificirani glikoproteinski hormon za uporabu prema zahtjevu 13 ili zahtjevu 14, ili ne-terapeutski postupak prema zahtjevu 15 ili zahtjevu 16, naznačen time što je spomenuta životinja konj, govedo, ovca ili svinja.
18. Polipeptid alfa podjedinice prema zahtjevu 1, naznačen time što je spomenuti polipeptid alfa podjedinice polipeptid divljeg tipa goveđe alfa podjedinice (SEQ ID NO:2) koji sadrži:
(A) polipeptid Asparagin-Valin-Treonin-Izoleucin-Asparagin-Valin (NVTINV) (SEQ ID NO:1) umetnut odmah nakon pozicije 6 spomenutog polipeptida alfa jedinice; i
(b) supstitucije za arginin (R) na pozicijama 15, 17, 18, 20 i 24.
19. Polipeptid alfa podjedinice prema zahtjevu 1 koji sadrži sekvencu amino kiseline SEQ ID NO: 7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677331P | 2012-07-30 | 2012-07-30 | |
| PCT/US2013/052510 WO2014022283A2 (en) | 2012-07-30 | 2013-07-29 | Glycoprotein hormone long-acting superagonists |
| EP13826476.7A EP2880164B1 (en) | 2012-07-30 | 2013-07-29 | Glycoprotein hormone long-acting superagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190847T1 true HRP20190847T1 (hr) | 2019-09-06 |
Family
ID=49995487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190847TT HRP20190847T1 (hr) | 2012-07-30 | 2019-05-07 | Dugodjelujući superagonisti glikoproteinskog hormona |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9187545B2 (hr) |
| EP (4) | EP3533874A1 (hr) |
| JP (1) | JP6429774B2 (hr) |
| CN (3) | CN112458096A (hr) |
| AR (1) | AR091936A1 (hr) |
| AU (2) | AU2013296709B2 (hr) |
| BR (1) | BR112015001885B1 (hr) |
| CA (2) | CA2880520C (hr) |
| DK (2) | DK3572515T3 (hr) |
| ES (2) | ES2894135T3 (hr) |
| HR (1) | HRP20190847T1 (hr) |
| HU (1) | HUE044016T2 (hr) |
| MX (1) | MX360717B (hr) |
| NZ (1) | NZ707016A (hr) |
| PL (2) | PL2880164T3 (hr) |
| PT (2) | PT3572515T (hr) |
| RS (1) | RS58881B1 (hr) |
| RU (2) | RU2018132561A (hr) |
| UA (1) | UA118653C2 (hr) |
| WO (1) | WO2014022283A2 (hr) |
| ZA (1) | ZA201502778B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6429774B2 (ja) | 2012-07-30 | 2018-11-28 | トロホジェン・インコーポレーテッド | 糖タンパク質ホルモン長期作用性スーパーアゴニスト |
| US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
| BR112016009962A2 (pt) | 2013-11-05 | 2017-12-05 | Trophogen Inc | superagonistas de ação prolongada de hormônio glicoproteico |
| BR102015032660B1 (pt) | 2015-12-28 | 2019-05-28 | Ouro Fino Saúde Animal Participações S.A. | PROCESSO DE PRODUÇÃO DE UMA GONADOTROFINA CORIÔNICA EQUINA RECOMBINANTE (reCG): COMPOSIÇÃO VETERINÁRIA E USO |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196123A (en) | 1978-11-20 | 1980-04-01 | Eugenia Rosemberg | Hybrid chorionic gonadotropin preparations and methods for stimulating ovulation using same |
| JPS6176421A (ja) | 1984-04-03 | 1986-04-18 | セロノ ラボラトリ−ズ インコ−ポレイテツド | 排卵誘発方法およびインビトロ受精方法 |
| US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| DE3751602T2 (de) | 1987-05-12 | 1996-05-02 | Serono Pharm Praep | Subkutane Verabreichung des humanen Choriongonadotropins. |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| AU4076589A (en) | 1988-09-01 | 1990-04-02 | Applied Research Systems Ars Holding N.V. | Methods for producing gonadotropin and tsh super-agonists |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| EP0404458A3 (en) | 1989-06-19 | 1992-03-04 | Bunge (Australia) Proprietary Limited | Ovine follicle stimulating hormone |
| DE69131978T2 (de) | 1990-05-08 | 2000-10-05 | Univ New Jersey Med | Glykoproteinhormon-analoga mit veränderten immunologischen merkmalen, veränderter wirksamkeit und/oder rezeptorspezifität |
| DE69120089T2 (de) | 1990-07-31 | 1996-12-12 | Liposome Co Inc | Anhäufung von aminosäuren und peptiden in liposomen |
| US5612034A (en) | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
| CA2131630A1 (en) | 1992-03-10 | 1993-09-30 | Yury E. Khudyakov | Exchangeable template reaction |
| US5604198A (en) | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
| RU2213099C2 (ru) * | 1994-08-12 | 2003-09-27 | Вашингтон Юниверсити | Одноцепочечный белок, модулятор гормонов лютеинизирующего, фолликулостимулирующего, тиреостимулирующего и хорионического гонадотропина (варианты), молекула нуклеиновой кислоты (варианты), вектор (варианты), линия трансформированных клеток сно (варианты), способ продуцирования одноцепочечного белка (варианты) |
| US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US7005505B1 (en) | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US6361992B1 (en) | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
| EP1947117B1 (en) | 1996-05-08 | 2013-07-17 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glycoprotein hormone superagonists |
| ATE306546T1 (de) | 1996-08-23 | 2005-10-15 | Ludwig Inst Cancer Res | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
| AU4984697A (en) | 1996-10-11 | 1998-05-11 | The Texas A & M University System | Methods for the generation of primordial germ cells and transgenic animal species |
| US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| US6485942B1 (en) | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
| US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
| DE69841063D1 (de) * | 1997-06-25 | 2009-09-24 | Merck Serono Sa Coinsins | Disulfid-vernetzte Glycoprotein-Hormone, ihre Herstellung und Verwendung |
| US6281408B1 (en) | 1998-02-20 | 2001-08-28 | Thomas Jefferson University | Efficient method for production of compound transgenic animals |
| EP1115866A1 (en) | 1998-09-22 | 2001-07-18 | University of Maryland at Baltimore | Cystine knot growth factor mutants |
| ATE324902T1 (de) | 1998-11-02 | 2006-06-15 | Ludwig Inst Cancer Res | Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 |
| EP1169053A1 (en) * | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| AU5023300A (en) | 1999-05-20 | 2000-12-12 | Scios Inc. | Vascular endothelial growth factor variants |
| US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US20020127652A1 (en) | 2000-02-11 | 2002-09-12 | Schambye Hans Thalsgard | Follicle stimulating hormones |
| AU2002317333C1 (en) | 2001-08-01 | 2009-06-25 | University Of Bristol | VEGF isoform |
| US20070184023A1 (en) | 2003-10-30 | 2007-08-09 | Pharmexa A/S | Method for down-regulation of vegf |
| EP1682576A1 (en) * | 2003-11-06 | 2006-07-26 | Compugen Ltd. | Variants of human glycoprotein hormone alpha chain: compositions and uses thereof |
| WO2005072417A2 (en) | 2004-01-27 | 2005-08-11 | The Ohio State University Research Foundation | Vascular endothelial growth factors and methods of their use |
| WO2005089445A2 (en) | 2004-03-19 | 2005-09-29 | Trophogen, Inc. | Follicle stimulating hormone superagonists |
| CA2561545A1 (en) * | 2004-03-31 | 2005-10-27 | Trophogen, Inc. | Human glycoprotein hormone superagonists and uses thereof |
| CN101067118A (zh) * | 2007-04-24 | 2007-11-07 | 新疆农业科学院微生物应用研究所 | 一种重组牛促卵泡激素在毕赤酵母中的表达 |
| WO2011075606A2 (en) * | 2009-12-18 | 2011-06-23 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| JP6429774B2 (ja) | 2012-07-30 | 2018-11-28 | トロホジェン・インコーポレーテッド | 糖タンパク質ホルモン長期作用性スーパーアゴニスト |
| US9905908B2 (en) | 2014-01-14 | 2018-02-27 | Luxshare Precision Industry Co., Ltd. | Antenna structure with proximity sensor |
-
2013
- 2013-07-29 JP JP2015525484A patent/JP6429774B2/ja active Active
- 2013-07-29 WO PCT/US2013/052510 patent/WO2014022283A2/en active Application Filing
- 2013-07-29 CN CN202011095353.6A patent/CN112458096A/zh active Pending
- 2013-07-29 RS RS20190625A patent/RS58881B1/sr unknown
- 2013-07-29 PT PT19170014T patent/PT3572515T/pt unknown
- 2013-07-29 CA CA2880520A patent/CA2880520C/en active Active
- 2013-07-29 EP EP19166115.6A patent/EP3533874A1/en not_active Withdrawn
- 2013-07-29 UA UAA201500722A patent/UA118653C2/uk unknown
- 2013-07-29 PL PL13826476T patent/PL2880164T3/pl unknown
- 2013-07-29 EP EP21186472.3A patent/EP4012033A1/en active Pending
- 2013-07-29 EP EP13826476.7A patent/EP2880164B1/en active Active
- 2013-07-29 RU RU2018132561A patent/RU2018132561A/ru not_active Application Discontinuation
- 2013-07-29 PT PT13826476T patent/PT2880164T/pt unknown
- 2013-07-29 AU AU2013296709A patent/AU2013296709B2/en active Active
- 2013-07-29 EP EP19170014.5A patent/EP3572515B1/en active Active
- 2013-07-29 DK DK19170014.5T patent/DK3572515T3/da active
- 2013-07-29 ES ES19170014T patent/ES2894135T3/es active Active
- 2013-07-29 ES ES13826476T patent/ES2727659T3/es active Active
- 2013-07-29 CN CN201380047511.2A patent/CN104619846B/zh active Active
- 2013-07-29 CA CA3108181A patent/CA3108181A1/en active Pending
- 2013-07-29 HU HUE13826476A patent/HUE044016T2/hu unknown
- 2013-07-29 BR BR112015001885-8A patent/BR112015001885B1/pt active IP Right Grant
- 2013-07-29 CN CN202011090733.0A patent/CN112409472A/zh active Pending
- 2013-07-29 PL PL19170014T patent/PL3572515T3/pl unknown
- 2013-07-29 MX MX2015001414A patent/MX360717B/es active IP Right Grant
- 2013-07-29 RU RU2015103059A patent/RU2668174C2/ru active
- 2013-07-29 NZ NZ707016A patent/NZ707016A/en active IP Right Revival
- 2013-07-29 DK DK13826476.7T patent/DK2880164T3/da active
- 2013-07-30 US US13/954,690 patent/US9187545B2/en active Active
- 2013-07-30 AR ARP130102702A patent/AR091936A1/es unknown
-
2014
- 2014-06-19 US US14/309,317 patent/US9249205B2/en active Active
-
2015
- 2015-04-23 ZA ZA2015/02778A patent/ZA201502778B/en unknown
- 2015-08-20 US US14/831,124 patent/US10766941B2/en active Active
-
2018
- 2018-05-31 AU AU2018203815A patent/AU2018203815B2/en active Active
-
2019
- 2019-05-07 HR HRP20190847TT patent/HRP20190847T1/hr unknown
-
2020
- 2020-09-04 US US17/012,387 patent/US20210054041A1/en active Pending
-
2023
- 2023-04-05 US US18/296,005 patent/US20230357345A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190847T1 (hr) | Dugodjelujući superagonisti glikoproteinskog hormona | |
| Nakabayashi et al. | Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor | |
| PE20171380A1 (es) | Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada | |
| CL2012001657A1 (es) | Polipeptidos de somatotropina porcina porque comprende un aminoacido no codificado de manera natural; uso de dicho polipeptido porque sirve para prevenir infeccion en animal. | |
| AR013139A1 (es) | Analogos de hormonas glicoproteicas entrecruzados de disulfuro, uso de dichos analogos para preparar medicamentos, composicion farmaceutica, uso de dicha composicion para preparar medicamentos, y proceso para la preparacion de dichos analogos. | |
| Roser et al. | Superovulation in the mare: a work in progress | |
| JP2015524819A5 (hr) | ||
| Xia et al. | Cloning and expression analysis of the follicle-stimulating hormone receptor (FSHR) gene in the reproductive axis of female yaks (Bos grunniens) | |
| Çiftci | Estrogen and growth hormone and their roles in reproductive function | |
| Sower et al. | A lamprey view on the origins of neuroendocrine regulation of the thyroid axis | |
| Chaube et al. | Catfish gonadotrophins: cellular origin, structural properties and physiology | |
| Kumar et al. | Role of IGF 1 in male and female reproduction in bovines: a review | |
| RU2016117119A (ru) | Пролонгированного действия суперагонисты гликопротеинового гормона | |
| Scanes et al. | The anterior pituitary gland: Lessons from livestock | |
| Naz et al. | Effect of immunization with six sperm peptide vaccines on fertility of female mice. | |
| Panasiewicz et al. | Radiocompetition of secretory pregnancy-associated glycoproteins as chorionic ligands with luteal and uterine gonadotrophin receptors of pregnant pigs | |
| Han et al. | Oral SS-14 DNA Vaccine is More Potent than Oral SS-28 DNA Vaccine in Promoting Rat Lactation | |
| Hien | APPLICATIONS OF PMSG AND HCG IN ASSISTED REPRO-DUCTIVE TECHNOLOGY IN ANIMALS | |
| Thach et al. | Natural and recombinant equine Chorionic Gonadotropins past and future in animal reproductive technology. | |
| Lee et al. | Prostaglandin $ F_2 {\alpha} $ Controls Reactive Oxygen Species in Bovine Corpus Luteum | |
| Hien et al. | Effects of PMSG and HCG on estradiol and progesterone levels from common palm civets (Paradoxurus hermaphroditus) | |
| Derar et al. | Immunoreactive Insulin-like growth factor in plasma during pre-and post-partum periods of thoroughbred mares from which the newborn were removed: its pattern, physiological function and relation to other hormones | |
| Cabeza et al. | Development and characterization of a novel variant of long-acting bovine follicle-stimulating hormone (brscFSH). | |
| Park et al. | Effect of in vivo embryo production and pregnancy rate of embryo transfer following superovulation in Hanwoo and Chickso | |
| Kuru et al. | Mechanism of luteolysis and vasoactive agents in cows. |